Boothbay Fund Management’s Neuphoria Therapeutics NEUP Stock Holding History
Bought
Maintained
Sold
Other funds holding NEUP
LCM
Boothbay Fund Management's NEUP Position: Q3 2026 in Review
Boothbay Fund Management held its Neuphoria Therapeutics (NEUP) position steady in Q3 2026 at 14,000 shares worth $49.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1853.
Boothbay Fund Management first reported a position in NEUP in Q4 2025 and has held it in 4 quarters since. The position peaked at $61.2K in Q2 2026. 19 funds tracked by Wall St. Rank hold NEUP as of Q3 2026.
- Boothbay Fund Management held 14,000 shares of Neuphoria Therapeutics worth $49.8K as of Q3 2026.
- Boothbay Fund Management left its Neuphoria Therapeutics share count unchanged in Q3 2026.
- Neuphoria Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q3 2026, its #1853 holding.
- Boothbay Fund Management first reported a position in Neuphoria Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Boothbay Fund Management's Neuphoria Therapeutics position peaked at $61.2K in Q2 2026.
- 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q3 2026.
Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.